Phase I Study of Cetuximab in Combination With 5-fluoruracil, Mitomycin C and Radiotherapy in Patients With Anal Cancer Stage T2 (greater than 4 cm) - T4 N0-3 M0 or Any T N2-3 M0

Trial Profile

Phase I Study of Cetuximab in Combination With 5-fluoruracil, Mitomycin C and Radiotherapy in Patients With Anal Cancer Stage T2 (greater than 4 cm) - T4 N0-3 M0 or Any T N2-3 M0

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Mar 2017

At a glance

  • Drugs Cetuximab (Primary) ; Fluorouracil (Primary) ; Mitomycin (Primary)
  • Indications Anal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Mar 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Jan 2019.
    • 18 Nov 2015 Results published in the European Journal of Cancer
    • 02 Sep 2015 According to the the ClinicalTrials.gov record, planned end date changed to 1 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top